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H E A L T H  A N D  M E D I C I N E
The ferroportin Q248H mutation protects from anemia, 
but not malaria or bacteremia
John Muthii Muriuki1*, Alexander J. Mentzer2*†, Gavin Band2, James J. Gilchrist2,3, 
Tommy Carstensen4, Swaib A. Lule5,6, Morgan M. Goheen7,8, Fatou Joof7, Wandia Kimita1, 
Reagan Mogire1, Clare L. Cutland9, Amidou Diarra10, Anna Rautanen2, Cristina Pomilla4, 
Deepti Gurdasani4, Kirk Rockett2, Neema Mturi1, Francis M. Ndungu1, J. Anthony G. Scott1,6, 
Sodiomon B. Sirima10, Alireza Morovat11, Andrew M. Prentice7, Shabir A. Madhi9,  
Emily L. Webb6, Alison M. Elliott5,6, Philip Bejon1,12, Manjinder S. Sandhu4, Adrian V. S. Hill2,13,  
Dominic P. Kwiatkowski2,4, Thomas N. Williams1,12,14, Carla Cerami7, Sarah H. Atkinson1,3,12†
Iron acquisition is critical for life. Ferroportin (FPN) exports iron from mature erythrocytes, and deletion of the Fpn 
gene results in hemolytic anemia and increased fatality in malaria-infected mice. The FPN Q248H mutation (glutamine 
to histidine at position 248) renders FPN partially resistant to hepcidin-induced degradation and was associated 
with protection from malaria in human studies of limited size. Using data from cohorts including over 18,000 African 
children, we show that the Q248H mutation is associated with modest protection against anemia, hemolysis, and 
iron deficiency, but we found little evidence of protection against severe malaria or bacteremia. We additionally 
observed no excess Plasmodium growth in Q248H erythrocytes ex vivo, nor evidence of selection driven by malaria 
exposure, suggesting that the Q248H mutation does not protect from malaria and is unlikely to deprive malaria 
parasites of iron essential for their growth.
INTRODUCTION
Control of iron metabolism is fundamental to almost all known life. 
Malaria parasites and other infectious pathogens require iron to grow 
and multiply, and the human host has evolved to withhold iron from 
pathogens using iron-binding and chaperone transport proteins (1). 
Ferroportin (FPN), the sole known cellular iron exporter, is highly 
expressed in duodenal enterocytes, hepatocytes, and splenic macro-
phages to allow iron absorption, storage, and recycling (2). FPN is 
regulated by the iron hormone hepcidin in response to iron over-
load, erythropoiesis, and inflammation. Hepcidin reduces cellular 
iron export by inducing the internalization and degradation of FPN. 
A recent study showed that FPN is also abundantly expressed on 
mature red blood cells (RBCs) and that conditional deletion of the 
Fpn gene resulted in the accumulation of excess intracellular iron, 
hemolytic anemia, and increased parasitemia and death in malaria- 
infected mice (3).
In humans, a mutation in FPN, Q248H (glutamine to histidine 
at position 248), increases cellular iron export by rendering FPN 
partially resistant to degradation by hepcidin, resulting in a 60% 
decrease in intracellular iron in Q248H cells (4). The effects of 
enhanced iron export may vary depending on cell type, for example, in 
erythrocytes, it might protect from excess toxic iron and hemolytic 
anemia (3), or in hematopoietic progenitor cells may reduce iron 
availability for erythropoiesis, and in enterocytes and macrophages, 
it might increase iron absorption and recycling. Alternately, Q248H 
has also been shown to impair cellular iron export [retaining only 
25% of wild-type (WT) iron efflux] (5) or have no functional effect 
(6, 7). Previous studies, with limited sample sizes, have found conflict-
ing associations between Q248H and anemia or iron overload (table 
S1 and fig. S1). Moreover, by increasing cellular iron export, Q248H 
FPN could deprive intracellular pathogens, such as falciparum 
malaria or Salmonella, of iron, a nutrient critical for their growth. 
Since the Q248H mutation occurs only in African populations, it 
has been hypothesized that the variant has been positively selected 
due to protection from malaria (3). Using data from 18,320 children 
from across Africa and 380 pregnant women from The Gambia 
(Fig. 1), we tested the hypothesis that the Q248H mutation is asso-
ciated with protection from hemolytic anemia, iron deficiency, and 
intracellular pathogens such as malaria or invasive Salmonella.
RESULTS
Characteristics of study participants
Figure 1 shows the populations included in this study. We tested 
associations with anemia and measures of iron status among 3374 
children aged from 3 months to 7 years from community-based 
cohorts in Uganda, The Gambia, Burkina Faso, Kenya, and South 
Africa. Since sickness can alter measures of iron status, we selected 
healthy children living in the community with available stored 
samples. The Q248H mutation was observed among 10.5% of children, 
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confirming its presence in African populations (n = 355 Q248H carriers, 
342 heterozygotes and 13 homozygotes combined assuming a domi-
nant mode of action). The characteristics of the community-based 
cohorts are summarized in table S2. For the ex vivo studies, RBCs 
came from anemic but otherwise healthy children (n = 229) and 
pregnant women (n = 380) from The Gambia. For the clinical studies, 
we analyzed case-control data from genome-wide association studies 
of severe malaria in 11,982 children, 5489 hospitalized patients with 
severe malaria (n = 658 Q248H carriers), and 6493 matched controls 
(n = 1519 Q248H carriers) from The Gambia, Malawi, Kenya, and 
Ghana (8). For bacteremia, we analyzed data from 1536 hospitalized 
Kenyan children with positive blood cultures (n = 223 Q248H) and 2677 
matched community controls (n = 384 Q248H; Fig. 1 and Table 2) (9).
FPN Q248H is associated with modest protection against 
anemia and iron deficiency
We first evaluated the effect of the mutation on the risk of anemia 
in 2666 children with hemoglobin measurements. The prevalence of 
A
B
Fig. 1. Collections with biological samples and phenotype and genetic data available in humans to test associations between anemia, iron, malaria, and bacteremia 
traits and the FPN Q248H mutation. (A) Proportion of total individuals with samples and data available for iron-related traits, and the Q248H mutation are shown in a 
heatmap of green gradient, representing the proportion of individuals with biological samples available, stratified by population with longitude and latitude represented 
on a map of the African continent. (B) Individuals with genetic data available from the 1000 Genomes Phase 3 Project with sequence data available stratified by population 
with longitude and latitude represented on a map of the African continent. MCV, mean cell volume; sTFR, soluble transferrin receptor; ZPP, zinc protoporphyrin; CRP, 
C-reactive protein; erythrocyte* includes samples available for ex vivo Plasmodium growth assay.
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anemia (hemoglobin <11 g/dl) was lower in Q248H children (46.8%) 
compared with WT [53.7%; odds ratio (OR), 0.75; 95% confidence 
interval (CI), 0.57–0.98; P = 0.037; comparing Q248H heterozygote and 
homozygote carriers to noncarriers and using two-tailed tests through-
out; Fig. 2A and Table 1]. Mean hemoglobin concentrations were 
0.22 g/dl higher in Q248H children compared with WT (10.81 g/dl 
versus 10.59 g/dl; P = 0.036) (Fig. 2B and Table 1). The association 
between Q248H and hemoglobin concentrations was consistent across 
cohorts and by gender (figs. S2 and S3). A meta-analysis of the current and 
previous studies and of the individual cohorts showed that the mutation 
is associated with a significant increase in hemoglobin concentration 
(figs. S1 and S2). We similarly observed higher mean corpuscular hemo-
globin concentrations (MCHCs) in children carrying Q248H compared 
with WT (P = 0.017, Fig. 2C), but no evidence of a difference in mean 
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Fig. 2. FPN Q248H mutation is associated with protection from anemia, red cell hemolysis, and iron deficiency. The Q248H mutation renders FPN partially resistant 
to hepcidin degradation (4), increasing iron export through enterocytes, erythrocytes, and macrophages. The effects of Q248H on (A) anemia, (B) hemoglobin, (C) MCHC, 
(D) haptoglobin, (E) iron deficiency, (F) transferrin saturation (TSAT), (G) hepcidin, (H) ferritin, (I) soluble transferrin receptors (sTfR), (J) ZPP, and (K) inflammation indicate 
reduced hemolysis, limited effect on iron status, and no association with inflammation. Plotted values are geometric means except anemia, iron deficiency, and inflammation, 
which are percentages. All P values were two tailed and derived from regression models adjusted for age, sex, and cohort. GIT, gastrointestinal tract; DMT1, divalent metal transporter 1.
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corpuscular volume (Table 1). The low frequency of Q248H homo-
zygotes makes it difficult to distinguish heterozygote and homo-
zygote effects in these data, but estimated effects appear broadly 
consistent with the dominance model assumed above, with some 
exceptions that will require additional data to resolve (table S3). We 
hypothesized that the modestly increased hemoglobin concentrations 
and MCHCs observed in Q248H carriers could be due to reduced 
hemolysis and/or improved iron status.
To test the hypothesis that higher hemoglobin concentrations 
among Q248H children may be due to reduced hemolysis, we mea-
sured haptoglobin concentrations in 587 Gambian children (2 to 
6 years). We observed that Q248H carriers (n = 50) had higher 
geometric mean haptoglobin concentrations compared with WT 
(133.22 mol/liter versus 109.32 mol/liter;  = 0.20; 0.02, 0.38; 
P = 0.03), consistent with reduced hemolysis in Q248H children 
(Fig. 2D and Table 1). These findings support the hypothesis that 
reduced hemolysis may contribute to the higher hemoglobin con-
centrations observed in Q248H children.
We further hypothesized that higher hemoglobin levels could be 
due to enhanced absorption and recycling of iron among Q248H 
carriers, leading to improved iron status as previously observed in 
smaller studies (table S1). Among 3065 children, 1031 (33.6%) were 
iron deficient. The Q248H variant (n = 325) was associated with a 
23% reduction in the odds of iron deficiency (P = 0.046; comparing 
Table 1. The FPN Q248H mutation is associated with protection from anemia, hemolysis, and iron deficiency in community-based children. Analyses 
were adjusted for age, sex, and country. CRP, C-reactive protein; MCV, mean corpuscular volume; sTfR, soluble transferrin receptor; TSAT, transferrin saturation; 
ZPP, zinc protoporphyrin. 
Q248H* WT
Category All, n Q248H, n n (%) WT, n n (%) OR (95% CI) P
Anemia† 2666 237 111 (46.8) 2429 1305 (53.7) 0.75 (0.57 to 0.98) 0.037
Iron deficiency‡ 3065 325 98 (30.2) 2740 933 (34.1) 0.77 (0.60 to 0.99) 0.046
Iron deficiency 
anemia§ 2363 208 35 (16.8) 2155 435 (20.2)
0.77 (0.52 to 
1.14) 0.19
Inflammation║ 3149 334 66 (19.8) 2815 587 (20.9) 0.94 (0.70 to 1.25) 0.65
Biomarkers All, n Q248H, n Geometric mean (SD) WT, n
Geometric 
mean (SD)
Estimate
(95% CI) P
Hemoglobin,  
g/dl 2666 237 10.81 (1.15) 2429 10.59 (1.16)
0.21 (0.01 to 
0.40) 0.036
MCHC, g/dl 1537 131 33.10 (1.04) 1406 32.87 (1.04)
0.27 (0.05 to 
0.50) 0.017
MCV, fL 2324 205 72.98 (1.12) 2119 72.76 (1.12)
0.16 (−0.87 to 
1.19) 0.76
Haptoglobin, 
mol/liter 587 50 133.22 (1.98) 537 109.32 (1.87)
0.20 (0.02 to 
0.38) 0.030
Ferritin, g/liter 3065 325 20.80 (2.53) 2740 20.03 (2.84) 0.08 (−0.03 to 0.20) 0.16
Hepcidin, g/liter 3080 319 8.31 (3.48) 2761 7.33 (3.87) 0.14 (−0.02 to 0.30) 0.089
sTfR, mg/liter 3091 325 11.98 (1.66) 2766 13.30 (1.67) −0.07 (−0.16 to 0.01) 0.088
Iron, mol/liter 459 45 5.45 (1.91) 414 4.83 (2.35) 0.14 (−0.10 to 0.37) 0.25
Transferrin,  
g/liter 2380 258 2.62 (1.28) 2122 2.70 (1.27)
−0.06 (−0.14 to 
0.02) 0.14
TSAT, % 430 40 7.89 (2.13) 390 6.95 (2.62) 0.09 (−0.18 to 0.36) 0.52
ZPP, mol/mol 
heme 684 66 97.43 (1.80) 618 114.63 (1.77)
−0.17 (−0.31 to 
−0.03) 0.018
CRP, mg/liter 2403 263 1.08 (5.07) 2140 1.35 (5.44) −0.19 (−0.41 to 0.02) 0.079
ACT, g/liter 737 68 0.47 (1.34) 669 0.44 (1.30) 0.05 (−0.01 to 0.12) 0.12
*Heterozygotes and homozygotes.   †Anemia was defined as hemoglobin <11 g/dl.   ‡Iron deficiency was defined as plasma ferritin <12 or <30 g/liter in 
the presence of inflammation in children <5 years or <15 g/liter in children ≥5 years.   §Iron deficiency anemia was defined as iron deficiency with 
anemia.   ║Inflammation was defined as C-reactive protein >5 mg/liter or ACT >0.6 g/liter in The Gambia.
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Q248H heterozygotes and homozygotes to noncarriers) and iron 
deficiency anemia (P = 0.19; Table 1). We observed a trend toward 
improved iron status for individual measures of iron status among 
Q248H children; however, with the exception of zinc protoporphyrin, 
a sensitive indicator of iron deficiency (P = 0.018), none of the asso-
ciations reached conventional statistical significance (Fig. 2 and 
Table 1). Increased hepcidin expression is a major factor in the 
alteration of iron stores during inflammation [defined as C-reactive 
protein >5 mg/liter or 1-antichymotrypsin (ACT) >0.6 g/liter], and 
Q248H FPN may be partially resistant to hepcidin (4); thus, in 
secondary analyses, we stratified by inflammation. The prevalence 
of inflammation did not differ between Q248H and WT children 
(P = 0.65; Fig. 2K and Table 1). After excluding children with inflam-
mation, we observed a 30% reduction in the odds of iron deficiency 
among Q248H carriers [n = 2409; adjusted OR, 0.7; 0.5–0.9; P = 0.018; 
fig. S3C] and a significant increase in ferritin concentrations ( = 0.1; 
0.01–0.2; P = 0.037). We found no significant interaction with 
inflammation or gender in predicting iron status (fig. S3). We further 
stratified by low and high hepcidin (using a threshold of 5.5 ng/ml) 
but found no evidence of an interaction. Together, our findings suggest, 
in agreement with previous studies (table S1), that the Q248H mutation 
is associated with modestly improved iron status in African children.
Little evidence that FPN Q248H is associated with protection 
from malaria or bacteremia
It has been proposed that the FPN Q248H variant protects individuals 
from malaria (3). We used cell culture methods to evaluate Plasmodium 
falciparum growth rates in fresh washed erythrocytes from 229 Gambian 
children (6 to 27 months, 28 with the Q248H variant, of whom 2 
were homozygous) and 380 mid-pregnant women (53 with Q248H, 
of whom 4 were homozygous) participating in randomized controlled 
trials of hepcidin-guided iron supplementation (10, 11). Erythrocytes 
from carriers of the Q248H variant consistently supported slightly 
faster parasite growth than WT (P = 0.089 in children, P = 0.032 in 
pregnant women, and P = 0.004 for the women and children 
combined) (Fig. 3A). To test the hypothesis that Q248H would offer 
protection in the face of raised hepcidin (3), we subdivided by high 
and low plasma hepcidin. There was no significant interaction.
We then evaluated whether the Q248H variant protects children 
from malaria in clinical studies (8). The Q248H mutation was not 
significantly associated with severe malaria overall (e.g., OR, 0.91; 
0.81–1.01; for an effect of one or two copies of Q248H relative to WT; 
P = 0.08) or in individual cohorts (Table 2). Moreover, in subgroup 
analyses, the Q248H mutation was not significantly associated with 
cerebral malaria (OR, 0.90; 0.77–1.06; estimated across cohorts), 
severe malarial anemia (OR, 0.90; 0.71–1.16), or mortality (OR, 1.00; 
0.78–1.29; Table 2). Inclusion of genotypes at the sickle cell causing 
variant rs334, which is strongly associated with malaria susceptibility 
in these populations, did not affect these results (table S4). Moreover, 
parasite density did not differ by the Q248H mutation (Fig. 3B). The 
prevalence of mild malaria among community-based children also 
did not differ by Q248H (Table 2).
We further hypothesized that Q248H, by reducing intracellular 
iron, might protect from other intracellular pathogens such as non-
typhoidal Salmonella, a common cause of mortality among African 
children (12). Among 1536 hospitalized Kenyan children with posi-
tive blood cultures and 2677 matched community controls (9), we 
found that the Q248H mutation was not associated with protection 
from all-cause bacteremia (OR, 1.05; 0.88–1.26) or with protection 
from bacteremia due to nontyphoidal Salmonella (OR, 1.25; 0.84–1.98), 
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Fig. 3. Effect of FPN Q248H variant on parasite P. falciparum growth rates and parasite density. (A) Ex vivo parasite growth rates in fresh erythrocytes from Gambian 
children (6 to 29 months) and mid-pregnant women stratified by carriage of Q248H FPN mutation (Het, heterozygous; Hom, homozygous). Parasite growth rates are geometric 
means from log-transformed data from triplicate assays. See the Materials and Methods for details of the assays and the clinical trials from which the samples were derived. A total 
of 229 genotyped children contributed data on up to three visits each (days 0, 49, and 84 of iron supplementation) and 380 genotyped pregnant women contributed data 
on up to four visits each (days 0, 14, 49, and 84). P values were calculated by analysis of variance (ANOVA) with visit day as a covariate to allow for supplementation effect. 
There was no interaction with hemoglobin or anemia or with plasma hepcidin (as a continuous variable or as above or below the thresholds of 5.5 ng/ml in children and 2.5 ng/ml in 
pregnant women). In the combined analysis of women and children, there was no interaction with study, confirming that merging of the datasets was legitimate. 
(B) P. falciparum parasite densities in hospitalized Kenyan children with severe malaria stratified by carriage of Q248H. Parasite densities are geometric means from log-transformed data. 
N, severe malaria cases. P values were derived from regression models adjusted for age, sex, and cohort. *Q248H heterozygotes and homozygotes combined (n = 3 homozygotes).
 o
n
 Septem
ber 5, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Muriuki et al., Sci. Adv. 2019; 5 : eaaw0109     4 September 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
6 of 12
Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, 
or Staphylococcus aureus (Table 2 and table S4).
No evidence of FPN Q248H natural selection driven by 
malaria exposure
We used data from the 1000 Genomes Project (13) to confirm that 
the DNA variant (rs11568350) encoding for FPN Q248H was only 
observed in populations with African ancestry (Fig. 4). We found 
that the derived allele (adenine, encoding the histidine amino acid) 
varied from 1.5% (in the Kenyan Maasai population) to 9.6% (in 
Malawian individuals). We observed no evidence of deviation from 
the Hardy-Weinberg equilibrium (P = 0.079 to 1; table S5) or of 
significant levels of differentiation between populations [Fixation 
index (FST) range, 0 to 0.06]. We further compared the frequencies 
Table 2. Little evidence that FPN Q248H provides protection against severe malaria or invasive bacterial infection. All P values reflect two-tailed tests. 
NTS, nontyphoidal Salmonella; RR, relative risk. 
Outcome All Q248H* WT RR/OR
(95% CI)
P
Malaria susceptibility†
Mild malaria 260/2,550 (10.2%) 25/232 (10.8%) 235/2,318 (10.1%) 1.06 (0.68–1.64) 0.79
Severe malaria‡ 5,489/11,982 (45.8%) 658/1519 (43.3%) 4,831/10,463(46.1%) 0.91 (0.81–1.01) 0.08
 (The Gambia§) 2,419/4,910 (49.3%) 225/479 (47.0%) 2,194/4,431 (49.5%) 0.88 (0.73–1.07) 0.21
 (Malawi§) 1,023/2,345 (43.6%) 174/419 (41.5%) 849/1,926 (44.1%) 0.89 (0.72–1.10) 0.28
 (Kenya§) 1,446/2,924 (49.5%) 191/405 (47.2%) 1,255/2,519 (49.8%) 0.98 (0.79–1.22) 0.87
 (Ghana║) 601/1,803 (33.3%) 68/216 (31.5%) 533/1,587 (33.6%) 0.83 (0.59–1.17) 0.29
Cerebral malaria‡ 1,948/7,971 (24.4%) 249/1043 (23.9%) 1,699/6,928 (24.5%) 0.90 (0.77–1.06) 0.21
 (The Gambia§) 758/3,676 (20.6%) 60/356 (16.9%) 698/3,320 (21.0%) 0.73 (0.55–0.99) 0.04
 (Malawi§) 644/2,057 (31.3%) 116/373 (31.1%) 528/1,684 (31.4%) 0.95 (0.75–1.22) 0.71
 (Kenya§) 546/2,238 (24.4%) 73/314 (23.2%) 473/1,924 (24.6%) 1.00 (0.75–1.34) 0.99
Severe malarial anemia‡ 735/7,971 (9.2%) 82/1043 (7.9%) 653/6,928 (9.4%) 0.90 (0.71–1.16) 0.42
 (The Gambia§) 428/3,676 (11.6%) 43/356 (12.1%) 385/3,320 (11.6%) 0.96 (0.68–1.35) 0.82
 (Malawi§) 91/2,057 (4.4%) 12/373 (3.2%) 79/1,684 (4.7%) 0.69 (0.37–1.29) 0.24
 (Kenya§) 216/2,238 (9.7%) 27/314 (8.6%) 189/1,924 (9.8%) 0.93 (0.60–1.43) 0.74
Malaria-related death‡ 677/4,669 (14.5%) 86/571 (15.1%) 591/4,098 (14.4%) 1.00 (0.78–1.29) 0.99
 (The Gambia§) 309/2,335 (13.2%) 27/219 (12.3%) 282/2,116 (13.3%) 0.91 (0.59–1.39) 0.65
 (Malawi§) 200/1,018 (19.6%) 37/173 (21.4%) 163/845 (19.3%) 1.14 (0.76–1.71) 0.51
 (Kenya§) 168/1,316 (12.8%) 22/179 (12.3%) 146/1,137 (12.8%) 0.94 (0.58–1.52) 0.80
Bacteremia¶ 1,536/4,213 (36.5%) 223/607 (36.7%) 1,313/3,606 (36.4%) 1.04 (0.87–1.24) 0.68
 Streptococcus 
pneumoniae
426/4,213 (10.1%) 57/607 (9.4%) 369/3,606 (10.2%) 0.93 (0.69–1.26) 0.65
 NTS 180/4,213 (4.3%) 31/607 (5.1%) 149/3,606 (4.1%) 1.25 (0.83–1.87) 0.28
 Escherichia coli 151/4,213 (3.6%) 26/607 (4.3%) 125/3,606 (3.5%) 1.27 (0.82–1.97) 0.29
 Haemophilus influenzae 128/4,213 (3.0%) 12/607 (2.0%) 116/3,606 (3.2%) 0.64 (0.35–1.18) 0.15
 Staphylococcus aureus 175/4,213 (4.2%) 20/607 (3.3%) 155/3,606 (4.3%) 0.80 (0.50–1.30) 0.37
*Heterozygotes and homozygotes.   †Mild malaria was defined as P. falciparum positive slide measured in community-based cohorts in Uganda, The Gambia, 
Burkina Faso, and Kenya. Severe malaria was defined as positive for P. falciparum parasites and clinical features of severe malaria (8), including diagnosis of 
cerebral malaria, severe malarial anemia, and other clinical symptoms.   ‡Relative risk, CI, and P value were computed by fixed-effect meta-analysis of 
estimates from the three case-control cohorts and (where applicable) the Ghanaian trios.   §Association analysis estimated by logistic regression adjusted for 
the first five principal components. For severe malaria and malaria-related death, results reflect binomial logistic regression of the phenotype compared with 
controls. For severe malaria subphenotypes, results reflect multinomial logistic regression of cerebral malaria, severe malarial anemia, and other severe malaria 
cases compared with controls. A dominant mode of effect is assumed.   ║Counts reflect numbers of probands (affected children) and parents in 608 
Ghanaian trios. Relative risk, CI, and P value are computed using a transmission disequilibrium test. A dominant mode of effect is assumed.   ¶Bacteremia was 
defined as positive blood culture from hospitalized admission in Kilifi County Hospital in Kenya. Association analysis for all-cause bacteremia was estimated by 
logistic regression adjusted for sex and the first two principal components of genome-wide genotyping data to account for population structure. Pathogen-
specific P values and odds ratios were derived by multinomial logistic regression adjusted for sex and population structure.
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of the derived allele in African populations against estimates of 
maximal rates of P. falciparum infection prevalence in children aged 
2 to 10 years (Fig. 4) (14). We observed no correlation between the ob-
served allele frequencies and parasite prevalence [Spearman rho = 0.27 
between rs11568350 adenine allele and the maximum estimated prev-
alence between the years 1900 and 1959, P = 0.37 (fig. S4A); or between 
the years 2000 and 2015, rho range = −0.17 to 0.25, P = 0.34 to 0.97 
(fig. S4B)], and one of the highest observed frequencies was in the 
South African population (8.4%), which has historically experienced 
low malaria transmission. Moreover, we noted the existence of a large 
number of other alleles across the genome in African populations with 
frequency characteristics equivalent to the FPN mutation (table S6).
DISCUSSION
The FPN Q248H variant is prevalent in African populations and is 
thought to have been naturally selected to confer protection against 
malaria and other intracellular infections by increasing iron efflux 
from erythrocytes (3). Here, we report findings from large-scale 
genomic datasets evaluating the effect of the Q248H mutation on 
anemia, iron status, malaria, and bacterial infections. We found that 
the mutation was associated with modest protection against anemia 
and iron deficiency but found little evidence that the mutation was 
associated with protection against malaria or invasive bacterial 
infections. We further showed that the Q248H mutation does not 
appear to have been selected in African populations due to malaria 
exposure.
The Q248H mutation was associated with a modest reduction in 
the risk of anemia and modestly improved hemoglobin concentrations. 
The Q248H variant has previously been associated with trends 
toward both lower and higher hemoglobin concentrations in studies 
of small sample size (fig. S1 and table S1). A meta-analysis of the 
current and previous studies indicates an overall increase in hemo-
globin concentrations in Q248H carriers (fig. S1). Higher hemoglobin 
concentrations might be due to higher iron efflux from Q248H 
erythrocytes protecting the cell from hemolysis (3). We observed 
higher concentrations of haptoglobin among Q248H carriers, indicat-
ing reduced levels of hemolysis. These findings are consistent with a 
previous report in a mouse model, which demonstrated that FPN, 
by reducing intracellular accumulation of iron and oxidant species, 
prevents hemolytic anemia and maintains red blood cell integrity (3). We 
further hypothesized that reduced hepcidin-induced degradation of 
Burkina Faso
The Gambia
Controls Cases
Controls Cases
Sierra Leone
Yoruba from Nigeria
Esan from Nigeria
Uganda
Luhya from Kenya
Maasai from Kenya
Kenya
Controls Malaria
cases
Bacteria
cases
Ghana
Malawi
ControlsCases
South Africa
Pie chart rs11568350 adenine
population allele frequency (%)
25 50 75
Composite maximal median
parasite prevalence (1900–1959)
2.5 5.0 7.5
Fig. 4. Frequencies of adenine allele of rs11568350 encoding the Q248H mutation in African populations compared with the composite maximal estimate of 
P. falciparum transmission in 2- to 10-year-olds between the years 1900 and 1959. Regional median estimates of transmission are provided across malaria endemic regions 
of the natural extent of sub-Saharan Africa including the Island of Madagascar as obtained from Snow et al. (14). Population-specific frequencies of the variant encoding 
the Q248H allele are shown as pie charts for each of the included populations with the more common ancestral allele colored in black and the rarer adenine allele colored. 
For illustration purposes, colors are assigned on a scale matched to the P. falciparum parasite prevalence scale using a frequency of 10% as equivalent to a prevalence of 1 
(for example, green represents 5% allele frequency). If there were a correlation between the allele frequencies and malaria prevalence, one would expect to see similar colors 
in the pie chart slices and map contours. The allele frequencies and estimated maximal estimates of transmission per population are plotted against each other in fig. S4.
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FPN among Q248H carriers might lead to improved iron absorption 
by duodenal enterocytes and iron recycling by macrophages. Consist-
ent with this hypothesis, we observed a trend toward improved iron 
status among children carrying the mutation corroborating findings 
from other studies (15–18). Zinc protoporphyrin levels were also 
significantly lower among Q248H individuals, suggesting no evidence 
for iron-deficient erythropoiesis, as previously suggested (3).
It has been proposed that FPN Q248H protects from malaria by 
depriving the parasite of iron within the red cell (3). However, we 
did not find a significant association between the mutation and 
malaria susceptibility in ex vivo or clinical studies. We found, instead, 
that erythrocytes from Q248H carriers supported slightly faster 
P. falciparum growth rates in ex vivo studies. Together, our data in 
large-scale studies suggest that any protection afforded by the Q248H 
mutation in natural populations is weak, with previous estimates of 
effect size (3) not generalizing to the phenotypes and populations 
considered here. In addition, the current study included 658 Q248H 
children with severe malaria, in contrast to a previous report with a 
limited sample size of 13 Q248H children with uncomplicated malaria 
and 11 Q248H women with placental malaria (3). These findings 
suggest that erythrocyte iron may not be an important source of iron 
for the malaria parasite.
Further, the FPN Q248H mutation was not associated with protec-
tion against all-cause bacteremia. Since the mutation may reduce 
intracellular iron, we specifically aimed to investigate whether the 
mutation is associated with susceptibility to nontyphoidal Salmonella, 
an intracellular pathogen, but found no evidence of protection, sug-
gesting that nontyphoidal Salmonella may acquire iron through other 
mechanisms. Previous studies have found either no association 
or increased susceptibility to tuberculosis (another intracellular 
infection) in the Q248H mutation compared with the WT in small 
cohorts (19, 20).
Given the lack of evidence for association between the Q248H 
mutation and multiple severe infectious diseases, we reevaluated the 
evidence that natural selection has driven the evolution of this variant 
(3). We found no correlation between the FPN Q248H derived 
allele and autochthonous P. falciparum prevalence. For instance, the 
derived allele frequency was highest in South Africa, a malaria-free 
population, thus suggesting that P. falciparum prevalence in the 
population is not associated with the mutation and arguing against 
selective pressure due to malaria. The low observed frequency of the 
Q248H allele outside Africa may have resulted from the loss of neutral 
allelic diversity that occurred as humans expanded out of Africa (21) 
rather than through a natural selection process. Together, these 
results provide little evidence for selection or for a relationship be-
tween the historical burden of malaria infection and the frequency 
of the Q248H mutation among populations.
In conclusion, using large-scale genomic datasets from African 
populations, we found that the Q248H mutation was associated 
with modest reductions in the risk of anemia and iron deficiency, 
which may be putatively due to reduced hemolysis and modestly 
improved iron status in Q248H carriers. These findings in large 
epidemiological studies build support for proposed biological path-
ways observed in mouse models (3), although the observed effect 
sizes are small and may not be clinically significant at an individual 
level. Last, we found little evidence that the Q248H mutation protects 
against malaria in ex vivo studies or against malaria or bacteremia 
in clinical studies and, finally, no evidence of positive selection of 
the variant attributable to malaria exposure.
MATERIALS AND METHODS
Study populations
The samples and data used in these analyses were sourced from 
multiple individual studies, many of which have data already avail-
able to general researchers. Participants from three countries (Uganda, 
South Africa, and Burkina Faso) were recruited into the VaccGene 
study with a primary aim of identifying genetic variants associated 
with differential response to vaccination in infancy but with ethical 
approval to undertake analyses investigating the effect of iron me-
tabolism on susceptibility to infection. Individuals from each of the 
individual populations were included if their dates of birth, vacci-
nation, and blood sampling were available and if it was confirmed 
that they had received three doses of routine vaccines and a single 
dose of measles vaccine by 12 months of age. Children were not 
further excluded on the basis of gender, ethnicity, HIV exposure, 
or any other health status. A range of clinical and demographic 
metadata were collected from the three cohorts, including the num-
ber of illnesses during the first year of life, details regarding the 
pregnancy and parental occupations, and self-reported ethnicities. A 
more detailed description of each of the populations follows below.
Uganda: The Entebbe Mother and Baby Study
The Entebbe Mother and Baby Study (EMaBS) is a prospective birth 
cohort that was originally designed as a randomized controlled trial 
to test whether anthelminthic treatment during pregnancy and early 
childhood was associated with differential response to vaccination 
or incidence of infections such as pneumonia, diarrhea, or malaria 
(http://emabs.lshtm.ac.uk/) (22). EMaBS originally recruited 2507 women; 
2345 live births were documented, and 2115 children were still 
enrolled at 1 year of age. Pregnant women in the second or third 
trimester were enrolled at the Entebbe Hospital antenatal clinic if 
they were residents in the study area, planning to deliver in the 
hospital, willing to know their HIV status, and willing to take part 
in the study. They were excluded if they had evidence of possible 
helminth-induced pathology (severe anemia, clinically apparent 
liver disease, or bloody diarrhea), if the pregnancy was abnormal, or 
if they had already enrolled during a previous pregnancy. The mothers 
and infants underwent intensive surveillance during the first year of 
infant life. Blood samples were taken and stored from both mother 
and cord blood around the time of birth. Samples, including whole 
blood, were subsequently obtained from the child annually on or 
around their birthday (2 to 5 ml depending on the age). The child’s 
samples were subsequently divided into plasma and red cell pellets 
as described in more detail below (23). Infants were included in the 
present study if (i) receipt of three doses of DTwP (a combination of 
diphtheria and tetanus toxoids and inactivated ‘whole’-cell pertussis 
organism vaccine)/Hib (Haemophilus influenzae type b)/HBV (hepa-
titis B virus) (at approximately 6, 10, and 14 weeks of age) and one 
dose of measles vaccine (at approximately 9 months of age) could 
be confirmed from their vaccination records, (ii) DNA could be 
extracted from stored red cell pellets, and (iii) plasma samples 
were available from the 12-month age point of sampling. Ethical 
approval was provided locally by the Uganda Virus Research Institute 
(reference GC/127/12/07/32) and Uganda National Council for Science 
and Technology (MV625), and in the United Kingdom by the London 
School of Hygiene and Tropical Medicine (A340) and Oxford Tropical 
Research (39-12 and 42-14) Ethics Committees.
South Africa: The Soweto Vaccine Response Study
Six-month old infants born in Chris Hani Baragwanath Hospital 
living in the Soweto region of Johannesburg, South Africa, were 
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identified from screening logs and databases of participants involved 
in clinical vaccine trials (24) coordinated by the Respiratory and 
Meningeal Pathogens Unit (www.rmpru.com/). Mothers of the 
infants were approached if the infants had received all of their 
vaccines up to 6 months of age (DTaP/Hib/HBV at approximately 
4, 8, and 12 weeks of age). After receiving information about the 
study, the mothers were consented in accordance with ethical approval 
from the University of Witwatersrand Human Research Ethics 
Committee (reference M130714) and the Oxford Tropical Research 
Ethics Committee (1042-13 and 42-14). The infants were sampled 
prospectively at 6 months of age and at 12 months after receipt of 
measles vaccine at 9 months. Single whole-blood samples were col-
lected and prepared using a similar protocol to that used in Entebbe 
to extract DNA from cell pellets and plasma for antibody assays.
Burkina Faso: The VAC050 ME-TRAP malaria vaccine trial
Infants between the ages of 6 and 18 months living in the Banfora 
region of Burkina Faso were recruited into a phase 1/2b clinical trial 
to test the safety, immunogenicity, and efficacy of an experimental 
heterologous viral-vectored prime-boost liver-stage malaria vaccine 
(25). These infants were all expected to receive their EPI (Expanded 
Programme on Immunization) vaccines as part of the usual national 
schedule (4, 8, and 12 weeks of age). Infants were precluded from 
participating in the trial if they were found to have clinical or hema-
tological (venous hemoglobin <8 g/dl) evidence of severe anemia, 
history of allergic or neurological disease, or malnutrition. Of a total 
of 730 infants who were recruited into the study, samples suitable 
for extraction of DNA were collected and stored from 400 infants 
(350 vaccine recipients and 50 recipients of a control rabies vaccine). 
Samples of plasma were available from the infants at multiple time 
points following receipt of the experimental vaccine. Samples from 
individuals taken at time points as close to the 12-month age as possible 
were prioritized for EPI vaccine response measurements. The infants 
underwent intensive clinical history and examination during screening 
and follow-up. The mothers of the participating infants provided con-
sent for their children to be enrolled in the clinical trial and for sub-
sequent genetic studies to be undertaken for all vaccines received in 
accordance with ethical approval from the Ministere de la Recherche 
Scientifique et de l’Innovation in Burkina Faso (reference 2014-12-151) 
and the Oxford Tropical Research Ethics Committee (reference 41-12).
Other study populations
The Gambia: West Kiang study
All children aged 2 to 6 years (except those with chronic illness) were 
recruited from 10 rural villages in the West Kiang region of The 
Gambia during the malaria season (July to August 2001) (26). Ethnic 
groups were Mandinka (9 villages, 700 children) and Fulani (1 village, 
80 children). All children had a clinical examination, anthropometric 
measurements, and a 3-day course of mebendazole for potential 
hookworm infection. A blood sample was collected for complete blood 
count, malaria slide, iron status assays, haptoglobin concentrations, 
ACT (a marker of inflammation), and DNA extraction. Children 
with a temperature >37.5°C had a malaria blood film, appropriate 
clinical treatment, and a blood sample 2 weeks later after recovery 
from illness. Parental written informed consent was obtained for all 
study participants. Ethical approval was provided by the Gambian 
government/Medical Research Council Ethics Committee (874/830).
Kenya: Ngerenya community-based cohort
This is an ongoing rolling cohort evaluating malaria immunity in 
children at the KEMRI-Wellcome Trust Research Programme as 
described elsewhere (27). Briefly, children were followed-up to a 
maximum age of 13 years with annual cross-sectional bleeds. The 
follow-ups involved weekly visits to assess for fever and tempera-
ture. If temperature was above 37.5°C, a malaria blood film was 
taken, and if positive, treatment was provided. Iron and inflam-
matory biomarkers and red cell indices were measured from a single 
cross-sectional bleed based on the availability of plasma samples 
archived at −80°C.
Other data used in this study are described elsewhere including 
case-control analyses of severe malaria in children from Kenya, 
Malawi, The Gambia, and Ghana recruited and analyzed as part 
of MalariaGEN (www.malariagen.net/data/genome-wide-study- 
resistance-severe-malaria-eleven-populations) (8) and the Kenyan 
bacteremia study (9). The individuals involved in coordinating, 
recruiting, and managing the samples and data from the Kenyan 
bacteremia study are listed in Appendix A.
Laboratory methods
Blood sampling and preparation
Whole blood was sampled into vacutainer tubes (BD, Becton 
Dickinson and Company, New Jersey, USA) containing ethylenedi-
aminetetraacetic acid (for the Ugandan and South African studies) 
or lithium heparin (Burkinabe, Kilifi, and West Kiang) as an anti-
coagulant in all five populations. Following centrifugation, the sam-
ples were separated into their constituent parts (plasma, buffy coat, 
and red cell/erythrocyte layers) and stored at −80°C until down-
stream analysis in batches. DNA was extracted from the erythrocyte 
layer in the Ugandan study and from the buffy coat in the South 
African, Burkinabe, Kilifi, and West Kiang studies. DNA from all 
cohorts was extracted from the relevant samples using the Qiagen 
QIAamp DNA Mini or Midi Kits (Qiagen, Hilden, Germany) using 
recommended protocols. Whole blood was also sampled into serum 
separator tubes (SST; BD, New Jersey USA) in the Ugandan study, 
and serum was isolated and stored according to the recommended 
protocols.
Laboratory assays
The assayed biomarkers of iron included plasma ferritin [Chemi-
luminescent Microparticle Immunoassay (CMI), Abbott Architect, 
USA], iron (MULTIGENT iron calorimetric assay, Abbott Architect, 
USA), transferrin (CMI, Abbott Architect, USA), and zinc proto-
porphyrin (Aviv Biomedical Hematoflurometer within 24 hours of 
collection). Hepcidin was assayed by using the DRG Hepcidin 25 
(bioactive) high-sensitive ELISA (enzyme-linked immunosorbent 
assay) Kit (DRG International, USA) in Uganda, South Africa, 
Burkinabe, and Kilifi, or by using the Hepcidin-25 (human) EIA 
(enzyme immunoassay) Kit (Bachem, Switzerland) in West Kiang. 
Soluble transferrin receptor was assayed by using the Human Soluble 
Transferrin Receptors (sTfR) ELISA (BioVendor, Czech Republic) 
in Uganda, South Africa, Burkina Faso, and Kilifi, or by the Quantikine 
sTfR ELISA Kit (R&D Systems, USA) in West Kiang. Since bio-
markers of iron are influenced by inflammation, C-reactive protein 
(MULTIGENT CRP Vario assay, Abbott Architect, USA in Uganda, 
South Africa, Burkina Faso, and Kilifi) or ACT (Immunoturbidimetry, 
Cobas Mira Plus Bio-analyzer, Roche in West Kiang) was assayed to 
adjust for inflammation (28). The red cell parameters including 
hemoglobin were analyzed using the Medonic CA 530 Oden 16 
hemoglobinometer. Haptoglobin concentrations were analyzed 
using the Tina Quant Haptoglobin Kit, Roche Diagnostics, Cobas 
Bio centrifugal analyzer (West Kiang).
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Genotyping and SNP quality control
The single single-nucleotide polymorphism (SNP) encoding the FPN 
Q248H mutation was directly genotyped in all populations, except 
Ghana, which is described further below. The VaccGene populations 
were all genotyped using the Illumina HumanOmni 2.5 M-8 (“octo”) 
BeadChip array version 1.1 (Illumina Inc., San Diego, USA), per-
formed by the Genotyping Core facilities at the Wellcome Trust 
Sanger Institute. Genomic DNA underwent whole-genome amplifi-
cation and fragmentation before hybridization to locus-specific 
oligonucleotides bound to 3-m-diameter silica beads. Fragments 
were extended by single-base extension to interrogate the variant by 
incorporating a labeled nucleotide enabling a two-color detection 
(Illumina). Genotypes were called from intensities using two cluster-
ing algorithms (Illuminus and GenCall) in GenomeStudio (Illumina 
Inc., San Diego, USA) incorporating data from proprietary pre-
determined genotypes.
SNP quality control (QC) was performed separately for each 
cohort using identical steps and using SNPs mapped to Human 
Genome Build 37. Low- quality variants that mapped to multiple 
regions within the human genome or did not map to any region were 
removed. Samples with a call rate of less than 97% and heterozygosity 
greater than 3 SDs around the mean were filtered sequentially. Sex 
check was performed in PLINK (v1.7) (http://zzz.bwh.harvard.edu/
plink/) using default F values of <0.2 for males and >0.8 for females. 
Samples with discordance between reported and genetic sex were re-
moved. Genetic variant filtering was performed across the remaining 
samples, and sites called in <97% samples were removed from each 
population. Identity by descent (IBD) was measured within each 
population. Only samples with IBD >0.9 not known to be twins were 
removed using an algorithm that removed the sample from the pair 
with the lower variant call rate. Sites in the Hardy-Weinberg dis-
equilibrium (P < 10−8) were also excluded from future analysis in all 
individuals, calculated using individuals with IBD <0.05 (hereafter 
designated “founders”). Following the above quality control 
steps, principal component analysis (PCA) was performed in 
EIGENSOFT v4.2 (www.hsph.harvard.edu/alkes-price/software/) for 
each population and combined with populations from the 1000 Ge-
nomes (13). PCA was carried out after linkage disequilibrium pruning 
to a threshold of r2 = 0.5 using a sliding window approach with a window 
size of 50 SNPs sliding 5 SNPs sequentially. Regions of long-range 
linkage disequilibrium were removed from the analysis. Individuals 
with values of the first 10 principal components >6 SDs around the 
mean of other samples in each population were removed. The variant 
encoding the FPN Q248H mutation was retained in all datasets follow-
ing the stringent quality control processes described: rs11568350 
(www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11568350).
For the Kenyan and Gambian community-based cohorts, the 
Q248H (rs11568350) mutation was directly typed using Agena Bio-
science SEQUENOM matrix-assisted laser desorption/ionization–
time-of-flight (MALDI-TOF) mass spectrometry on the iPLEX 
platform (29). Briefly genomic DNA was whole genome amplified 
using primer extension preamplification (30) before genotyping as per 
the manufacturer’s instructions for the iPLEX platform. Assay primers 
for Q248H were designed using the SpectroDESIGNER(R) primer 
design software and ordered from Metabion (www.metabion.com). 
Genotypes were called and curated by inspecting cluster plots us-
ing the SpectroTYPER software. The Q248H SNP had a call rate 
of 100% and was in the Hardy-Weinberg equilibrium (Pearson chi-
square P = 0.32).
Details of genotyping of the severe malaria cases, other than 
Ghanaian trio probands, and bacteremia cases and the 1000 Genomes 
project are described elsewhere (8, 9, 13). We selected the Q248H 
SNP from the genotyped data.
To obtain genotypes for Q248H in the Ghanaian trios, we down-
loaded the genotype array data from the European Genome-Phenome 
Archive (dataset ID EGAD00000000020) and implemented sample 
and SNP QC as suggested in the documentation. We used the strand 
file produced by W. Rayner (www.well.ox.ac.uk/~wrayner/strand/) 
for the Illumina Omni 650Y array to realign SNPs to Human Genome 
Build 37. We then used SHAPEIT2 to statistically phase genotypes 
genome-wide, based on the family trio structure and patterns of 
linkage disequilibrium. We imputed genotypes into the 1000 Genomes 
Phase 3 reference panel using IMPUTE2 (31). Q248H was imputed 
with high confidence (IMPUTE info = 0.99). We extracted Q248H 
from the imputed data for further analysis.
P. falciparum in vitro growth assay
In vitro parasite growth was assessed in fresh, washed RBCs for 96 
hours using the P. falciparum strain FCR3-FMG (MR4, MRA-736) 
as previously described (32). Other laboratory strains and field iso-
lates have previously been shown to yield similar results (32, 33). 
Briefly, synchronized parasite cultures were seeded as rings into 
RBCs from study participants in triplicate into 96-well plates at 0.5% 
initial parasitized RBCs in 20 × 106 RBC total per well (1% hematocrit) 
and maintained for 96 hours. Identical plates were set up in parallel 
for assaying precise 0-hour parasitemia in each blood sample. 
Growth rates represent the final 96-hour parasitemia divided by the 
initial 0-hour parasitemia, analyzed by flow cytometry staining for 
parasitized RBCs using DNA dye SYBR Green I (Invitrogen).
RBCs used were obtained from Gambian children and pregnant 
women enrolled in randomized trials of hepcidin-guided iron sup-
plementation (10, 11). Children (6 to 27 months) were screened as 
anemic (hemoglobin <11 g/dl) at enrollment but otherwise healthy, 
and blood was collected at days 0, 49, and 84 during 12 weeks of iron 
supplementation. Pregnant women (18 to 45 years) were estimated 
14 to 22 weeks’ gestation at enrollment, and blood was collected at 
days 0, 14, 49, and 84 during 12 weeks of iron supplementation. 
Growth rate data from all blood collection time points were analyzed 
in this study. Children contributed 1 to 3 data points and women 1 
to 4 data points. RBCs from healthy, iron-replete adult donors of 
normal hemoglobin genotype and G6PD (glucose-6-phosphate 
dehydrogenase) status not undergoing iron supplementation served 
as controls for interassay variability. Growth rates in the subjects’ 
RBCs were normalized to that in control RBCs assayed simultaneously. 
FPN genotyping for the Q248H polymorphism was performed 
using DNA extracted from the subjects’ blood (QIAamp DNA Blood 
Mini Kit, Qiagen) and Thermo Fisher’s TaqMan SNP assay (Thermo 
Fisher Scientific 4351379, protocol-MAN0009593). Statistical analyses 
were performed in DataDesk 7.0.2 (Data Description Inc., Ithaca, NY).
Definitions
Iron deficiency was defined as plasma ferritin <12 or <30 g/liter in 
the presence of inflammation (defined as C-reactive protein >5 mg/
liter or ACT >0.6 g/liter) in children <5 years, or <15 g/liter in 
children ≥5 years (28). Anemia was defined as hemoglobin <11 g/dl 
(34). Iron deficiency anemia was defined as presence of iron defi-
ciency and anemia (34) . Malaria parasitemia was defined as asexual 
P. falciparum parasite positive. Severe malaria was defined as positive 
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for P. falciparum parasites in the blood film and clinical features of 
severe malaria as defined by World Health Organization criteria (8). 
Cerebral malaria was defined as a case of severe malaria with a 
Blantyre coma score of <3, and severe malarial anemia was defined 
as a case of severe malaria with a hemoglobin level of <5 g/dl or a 
hematocrit level of <15% (8). Bacteremia was defined as a positive 
pathogenic blood culture.
Statistical analysis
All statistical analyses of community-based cohorts were conducted 
using STATA 13.1 (StataCorp, College Station, TX). Individual iron 
markers were normalized by log transformation. Proportions were 
compared between groups by chi-square or Fisher’s exact test 
where appropriate, and continuous variables by Student’s t test or 
Mann-Whitney U test. Linear and logistic regression models were 
adjusted for age, sex, and cohort. Analyses of malaria and bacteremia 
cohorts were undertaken using logistic regression in R and multi-
nomial regression in SNPTEST (version 2.5), respectively. For 
the malaria case-control analysis undertaken for trios in Ghana, a 
transmission disequilibrium test was undertaken using the “trio” 
package in R. Meta-analyses were performed using the “metan” 
package in STATA.
Estimates of heterozygosity at the DNA variant encoding the FPN 
Q248H variant (using Fisher’s exact test) and FST (using the Weir and 
Cockerham method) were calculated using the “diveRsity” package 
available in R (35). To investigate the relationship between historical 
rates of malaria transmission, the minor allele frequencies of this variant 
within each population were compared with estimates of P. falciparum 
transmission rates estimated between 1900 and 1959 using data 
recently made publicly available (14). The maximal transmission rate 
for any geocoded region between 1900 and 1959 was used to create a 
composite measure that was expected to contribute most to natural 
selection, if present. Regions, including those where the populations 
were recruited from, were included in the analysis. Shapefiles were 
loaded and transformed using the “raster” (http://rspatial.org/), “sp” 
(https://edzer.github.io/sp/), and “rgdal” (www.gdal.org/) packages and 
then plotted and fortified using “ggplot2” (https://ggplot2.tidyverse.
org/) in R. As a comparison for more modern data, an equivalent 
method was used using data from the Malaria Atlas Project (MAP) 
spanning the years 2000–2015. GPS coordinates for study sites were 
uploaded to MAP (https://map.ox.ac.uk/), and the P. falciparum 
parasite rates in 2- to 10-year-olds in Africa were plotted against 
rs11568350-derived allele frequency and correlations were compared 
within years using Spearman rank tests of correlation.
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